Current Oncology. 2007 Aug;14(4):154-61. [Link] Buckstein R, Meyer RM, Seymour L, Biagi J, Mackay H, Laurie S, Eisenhauer E. Division of Hematology, Odette Cancer Center, Toronto, Ontario. Abstract Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (vegf) receptors 1,…

Read More